--- title: "IN8bio (INAB) stock listing, news and investor profile" url: "https://aibio.space/companies/in8bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IN8bio, Inc. (NASDAQ: INAB), United States. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- INAB IN8bio, Inc. NASDAQ · United States # IN8bio (INAB) news Company Updates · 2026-08-06 ## [IN8bio reports second quarter 2026 results and glioblastoma survival data](https://aibio.space/news/in8bio-reports-second-quarter-2026-results-glioblastoma-survival-data/) IN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs. ## Latest IN8bio news 1. 2026-05-07 Company Updates [IN8bio reports first quarter 2026 results and glioblastoma survival updates](https://aibio.space/news/in8bio-reports-first-quarter-2026-results-glioblastoma-survival/) IN8bio reported cash of $21.9 million at March 31, 2026 and a net loss of $5.1 million for the quarter, and it described updated glioblastoma data and its INB-619 engager program. 2. 2025-06-30 Listings [IN8bio regains compliance with Nasdaq $1.00 minimum bid price rule](https://aibio.space/news/in8bio-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/) Nasdaq notified IN8bio on June 24, 2025 that the company again meets Listing Rule 5550(a)(2). The exchange said the matter is now closed. 3. 2025-04-28 Financings [IN8bio expects about $1.9 million from reduced-price warrant exercises and exchanges](https://aibio.space/news/in8bio-expects-about-1-9-million-reduced-price-warrant-exercises/) Holders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45. ## IN8bio at a glance - **Ticker**: INAB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $18.1 million ### Related companies - [InVitro International](https://aibio.space/companies/invitro-international/) OTC: IVRO - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW - [REBUS HLDGS INC.](https://aibio.space/companies/rebus-hldgs/) OTC: RBSH - [PureTech Health](https://aibio.space/companies/puretech-health/) LSE: PRTC - [NovelStem International](https://aibio.space/companies/novelstem-international/) OTC: NSTM - [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) NASDAQ: LRMR - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA - [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) OTC: PARD ### Also on NASDAQ - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) SMMT - [Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON - [CVRx](https://aibio.space/companies/cvrx/) CVRX - [Alpha Tau Medical](https://aibio.space/companies/alpha-tau-medical/) DRTS - [Clene](https://aibio.space/companies/clene/) CLNN - [HARVARD BIOSCIENCE INC](https://aibio.space/companies/harvard-bioscience/) HBIO ## What IN8bio does IN8bio, Inc. describes itself as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers, called TCEs, for cancer and autoimmune diseases. The business section explains that gamma-delta T cells are a specialized population of naturally occurring immune cells that can regulate immune responses and differentiate between healthy and diseased tissue. It says these cells act as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation. The company states that multiple studies have demonstrated the robust tumor-killing ability of gamma-delta T cells. The text available for this profile ends early in the business overview, so individual product candidates, their development stages and any partners are not described in it. Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/inab-20251231.htm). ## IN8bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$10.2 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | [$17.0 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | | Net income (loss) | [-$19.4 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | [-$30.4 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | | Cash from operations | [-$12.7 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | [-$24.1 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/) | | Cash and equivalents | [$27.3 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526338012/) | [$11.4 million](https://www.sec.gov/Archives/edgar/data/1740279/000119312526338012/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about IN8bio What is the ticker symbol of IN8bio? IN8bio, Inc. trades under the ticker INAB on NASDAQ. Where is IN8bio listed? IN8bio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6JH0. What is the SEC CIK of IN8bio? The SEC Central Index Key (CIK) for IN8bio, Inc. is 1740279. Its filings are on SEC EDGAR. How many shares does IN8bio have outstanding? 9,858,383 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is IN8bio listed under? Our directory records IN8bio, Inc. under United States. What does IN8bio do? Our directory classifies IN8bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of IN8bio? The ISIN recorded for IN8bio, Inc. is US45674E2081. Does aibio.space cover IN8bio? aibio.space lists IN8bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is IN8bio incorporated? SEC records list its state or country of incorporation as DE. What does IN8bio develop? IN8bio, Inc. describes itself as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers, called TCEs, for cancer and autoimmune diseases. The business section explains that gamma-delta T cells are a specialized population of naturally occurring immune cells that can regulate immune responses and differentiate between healthy and diseased tissue. Is IN8bio profitable? IN8bio, Inc. reported a net loss of $19.4 million for the fiscal year ended Dec 31, 2025, and used $12.7 million of cash in operations, per its annual report to the SEC. How much does IN8bio spend on research and development? $10.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does IN8bio have? $18.1 million in cash at Jun 30, 2026, per its 10-Q. What is the latest IN8bio (INAB) stock news? Our latest story on IN8bio, dated Aug 6, 2026: "IN8bio reports second quarter 2026 results and glioblastoma survival data". IN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs. [Source](https://aibio.space/news/in8bio-reports-second-quarter-2026-results-glioblastoma-survival-data/). What is IN8bio's latest stock offering or financing news? Our latest financing story, dated Apr 28, 2025: "IN8bio expects about $1.9 million from reduced-price warrant exercises and exchanges". Holders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45. [Source](https://aibio.space/news/in8bio-expects-about-1-9-million-reduced-price-warrant-exercises/). ## Investor discussion: IN8bio Members talk about IN8bio (INAB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at IN8bio, newest first. Each line links the filing it comes from. 1. 2025-12-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/d145007d8k.htm) 2. 2025-11-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525272565/d73909ds3.htm) 3. 2025-06-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525152037/d866741d8k.htm) 4. 2025-06-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525134487/d927529d8k.htm) 5. 2025-05-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525116901/d911601d8k.htm) 6. 2025-03-17 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525055610/d888198ddef14a.htm) 7. 2025-03-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525047254/d888198dpre14a.htm) 8. 2025-02-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.08). [Source](https://www.sec.gov/Archives/edgar/data/1740279/000119312525022711/d841361d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INAB on TradingView](https://www.tradingview.com/symbols/NASDAQ-INAB/). ## SEC filings and registration - **SEC name**: In8Bio, Inc. - **CIK**: 1740279 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: INAB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: EMPIRE STATE BUILDING, NEW YORK, NY, 10118 - **Phone**: (646) 600-6438 - **Shares outstanding**: 9,858,383 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Incysus Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1740279/000119312526338012/inab-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1740279/000119312526249684/d100941d8k.htm) filed 2026-06-01 - [424B5](https://www.sec.gov/Archives/edgar/data/1740279/000119312526249564/d18796d424b5.htm) filed 2026-06-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1740279/000119312526212135/inab-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1740279/000119312526126208/d26327ddef14a.htm) filed 2026-03-26 - [10-K](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104181/inab-20251231.htm) filed 2026-03-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001740279), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details IN8bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INAB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: IN8bio, Inc. - **Ticker**: INAB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45674E2081 - **Other listed symbols**: GETTEX:6JH0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INAB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/in8bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "IN8bio (INAB) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/in8bio/